Share markets in India are presently trading on a flat note. Sectoral indices are trading mixed with stocks in the realty sector, metal sector and power sector witnessing maximum buying interest while healthcare stocks and auto stocks are witnessing selling pressure.

The BSE Sensex is trading down by 54 points (down 0.1%), while the NSE Nifty is trading down by 18 points (down 0.2%). The BSE Mid Cap index is trading up 0.5% and the BSE Small Cap index is trading up by 0.3%.

The rupee is trading at Rs 70.24 against the US$.

In the news from the aviation space, Jet Airways share price is witnessing buying interest today on reports over revival steps.

The company is reworking its international network, cutting down unviable flights and adding new ones where it hopes to make money as the cash-strapped carrier tries to revive its fortunes while simultaneously seeking a cash infusion to keep itself afloat.

The company's financial woes have worsened by rising crude oil prices and intense pricing competition in the domestic aviation industry.

The company has been going through severe financial crush since last year. It has suffered three consecutive quarterly losses and is currently trying hard to make its turnaround plan aimed at reducing operational costs.

Jet Airways share price is presently trading up by 0.7%.

To know more about the company, you can access to Jet Airways' latest result analysis and Jet Airways' 2017-18 Annual Report Analysis on our website.

Moving on to the news from the pharma space, Sun Pharma share price plunged around 10% in early trade today, hitting a six-month low after various allegations of mis governance and insider trading.

Last Tuesday, a note by Macquarie, an Australian brokerage firm went viral which raised concerns among the investing community.

The note raised questions about inadequate disclosures regarding the role of promoter Dilip Shanghvi's brother-in-law Sudhir Valia, Sun Pharma's past links with banned traders Ketan Parekh and Dharmesh Doshi, related party transactions involving promoter Shanghvi and guarantees given to real estate firm Suraksha Realty.

The note also questioned the selection of little-known London-based firm Jermyn Capital to manage the drug major's $275 million foreign convertible bond issue in 2004-07.

The markets regulator reportedly is planning to reopen the investigation into the insider trading case against the company and its promoters which was settled through consent mechanism.

Responding to the above news, Sun pharma denied all the allegations and said the information which was already available in the public domain had been portrayed in a way to indicate that something inappropriate had been done by the company.

To know more about the company, You can read Sun pharma Q2FY19 result analysis and Sun pharma fact sheet on our website.

Speaking of pharma sector, note that the BSE Healthcare Index has been on a roller coaster ride in the past few years. The period from 2012 to 2015 saw the index go up more than three times.

And since then it has been a painful ride downwards, as can be seen from the chart below:

The Roller Coaster Ride of the BSE Healthcare Index

We believe that pharma companies that invest in creating a pipeline of complex generics or building competencies in alternative dosage forms are better equipped to tackle the changing dynamics in the US generics market as well as in the overall industry.

In the news from the commodity space, oil prices climbed around 5% after US and China agreed a truce in their trade conflict and ahead of a meeting by producer club Organization of Petroleum Exporting Countries (OPEC) this week that is expected to result in a supply cut.

The trade war between the world's two biggest economies has weighed heavily on global trade, sparking concerns of an economic slowdown. Reportedly, US oil production is expected to rise further in 2019 on high drilling activity.